{"id":"NCT01007149","sponsor":"Novartis Pharmaceuticals","briefTitle":"Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma","officialTitle":"A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2009-11-03","resultsPosted":"2012-06-08","lastUpdate":"2012-07-20"},"enrollment":79,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"omalizumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Omalizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal therapy.","primaryOutcome":{"measure":"Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils","timeFrame":"Baseline and 16 weeks","effectByArm":[{"arm":"Omalizumab","deltaMin":-84.4,"sd":17.8},{"arm":"Placebo","deltaMin":27.7,"sd":87.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":10,"countries":["France"]},"refs":{"pmids":["23579324"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":20},"commonTop":["Asthma","Headache","Cough","Bronchitis","Nausea"]}}